MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Motor evaluation of Parkinson’s disease patients through video consultations in the Brazilian public health system – a real life feasibility study

    D. Dos Santos, D. Camelo, M. Strelow, M. Silva, P. Führ, L. Marins, A. Schumacher-Schuh (Porto Alegre, Brazil)

    Objective: To assess the feasibility and quality of evaluating motor symptoms through video consultations for Parkinson disease’s (PD) patients in the Brazilian public health system.…
  • MDS Virtual Congress 2021

    WATCH-PD: Wearable Assessments in the Clinic and Home in Parkinson’s Disease: Baseline Analyses

    J. Adams, E. Dorsey, T. Ruiz Herrero, P. Auinger, R. Alexander, R. Rubens, B. Tracey, N. Zach, P. O'Donnell, A. Best, J. Severson, M. Kostrzebski, E. Stevenson, P. Wilmot, Y. Pohlson, J. Cosman, K. Fisher, J. Edgerton, T. Kangarloo (Rochester, USA)

    Objective: To provide a profile of early Parkinson’s disease (PD) using clinical and digital measures and determine whether digital measures can differentiate PD and controls…
  • MDS Virtual Congress 2021

    Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations

    G. Ebersbach, W. Poewe, J. Ferreira, D. Magalhaes, J. Rocha, P. Soares-da-Silva (Beelitz-Heilstätten, Germany)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation according to different levodopa daily intakes. Background: OPC proved…
  • MDS Virtual Congress 2021

    Effects of Opicapone on Sleep in Patients with Parkinson’s Disease and Motor Fluctuations

    R. Hauser, A. Videnovic, P. Soares-da-Silva, G. Liang, K. Olson, E. Jen, JF. Rocha, O. Klepitskaya (Miami, USA)

    Objective: To assess the effects of opicapone (OPC: 50 mg, once-daily) on sleep in patients with Parkinson’s disease (PD) and motor fluctuations. Background: OPC is…
  • MDS Virtual Congress 2021

    PARK-BAND training program for Parkinson’s disease in clinical settings: A feasibility study.

    D. Lima, J. Bonfadini, S. Almeida, E. Sobreira, P. Damasceno, M. Alencar, A. Viana-Júnior, J. Luna, P. Rodrigues, I. Pereira, A. Gadelha, P. Oliveira, E. Chaves, L. Oliveira, V. Gomes, R. Monteiro, T. Costa, L. Lima, M. Sobreira-Neto, P. Braga-Neto (Fortaleza, Brazil)

    Objective: To describe indicators of feasibility, including acceptability and safety, of Power training (PT) in Parkinson’s Disease (PD). Background: PT is a specific method of…
  • MDS Virtual Congress 2021

    Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America

    R. Pahwa, S. Fox, J. Hui, C. Singer, J. Schwarz, M F. de Pandis, J. Raw, I. Zhang, E. Pappert, B. Navia (Kansas City, USA)

    Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    The effect of Nordic Walking on respiratory function, pain and gait in Parkinson’s disease

    J. Stożek, W. Falewska, S. Podsiadło (Krakow, Poland)

    Objective: To assess the effect of rehabilitation program based on exercises and Nordic Walking (NW) on respiratory function, range of chest mobility, pain and gait…
  • MDS Virtual Congress 2021

    The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease

    S. Bido, J. Kūka, M. Makrecka-Kuka, G. Zheng, D. Keefe, V. Broccoli (Milan, Italy)

    Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…
  • MDS Virtual Congress 2021

    ABBV-0805, a novel α-synuclein oligomer selective antibody, prolonged lifespan and prevented accumulation of α-synuclein pathology in mouse models of Parkinson’s disease

    J. Fälting, F. Eriksson, J. Sigvardson, M. Johannesson, A. Kasrayan, M. Jones-Kostalla, P. Appelkvist, L. Söderberg, M. Blom, A. Rachalski, K. Nordenankar, O. Zachrisson, E. Amandius, G. Osswald, M. Moge, M. Ingelsson, J. Bergström, L. Lannfelt, C. Möller, M. Giorgetti, E. Nordström (Stockholm, Sweden)

    Objective: We report on the pharmacological characteristics of ABBV-0805 (BAN0805), a monoclonal antibody that exhibits a high selectivity for human α-synuclein oligomers and very low…
  • MDS Virtual Congress 2021

    Influence of onset of motor fluctuations on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

    W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva (Wolfach, Germany)

    Objective: This post-hoc analysis evaluated the influence of onset of motor fluctuation (OMF) on the response to opicapone (OPC) treatment in patients with Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley